Sanofi, Re­gen­eron and Ab­b­Vie lead phar­ma TV ad­ver­tis­ers in boom­ing 2023

Even as the ad in­dus­try laments a gen­er­al down­turn in tra­di­tion­al TV me­dia, phar­ma mar­keters are wrap­ping up a block­buster year. Phar­ma com­pa­nies plunked down $4.37 bil­lion, an in­crease of 8.8% over 2022, on na­tion­al TV com­mer­cials through mid-De­cem­ber, ac­cord­ing to re­al-time ad track­er iS­pot.tv.

Sanofi and Re­gen­eron’s Dupix­ent was the high­est-spend­ing drug brand, with a com­bined $297 mil­lion for in­di­ca­tions in both eczema and asth­ma. Ab­b­Vie’s Skyrizi fol­lowed among the top 10 lead­ers with $287 mil­lion spent across in­di­ca­tions for Crohn’s dis­ease and pso­ri­a­sis. Boehringer In­gel­heim’s Jar­diance was next with $143 mil­lion in its lone type 2 di­a­betes in­di­ca­tion, fol­lowed by Bris­tol My­ers Squibb’s So­tyk­tu ($132 mil­lion), an­oth­er Ab­b­Vie brand Vray­lar ($127 mil­lion) and No­vo Nordisk’s Ozem­pic ($125 mil­lion).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER